<DOC>
	<DOC>NCT00406094</DOC>
	<brief_summary>The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.</brief_summary>
	<brief_title>Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)</brief_title>
	<detailed_description>Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Aged 18 65 years Diagnosed with NARES Smokers, exposed to passive smoke Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or vasomotor rhinitis (VMR)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>NARES</keyword>
	<keyword>eosinophils</keyword>
	<keyword>nasal symptoms</keyword>
</DOC>